Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: Evidence for a proximal role in Alzheimer's disease by Dodson, S.E. et al.
Neurobiology of Disease
Loss of LR11/SORLA Enhances Early Pathology in a Mouse
Model of Amyloidosis: Evidence for a Proximal Role in
Alzheimer’s Disease
Sara E. Dodson,1 Olav M. Andersen,4 Vinit Karmali,1 Jason J. Fritz,1,2Dongmei Cheng,1,3 Junmin Peng,1,3
Allan I. Levey,1,2 Thomas E. Willnow,5 and James J. Lah1,2
1Center for Neurodegenerative Disease, Departments of 2Neurology and 3Human Genetics, Emory University, Atlanta, Georgia 30322, 4The MIND Center,
Department of Medical Biochemistry, Aarhus University, 8000 Aarhus, Denmark, and 5Max-Delbrueck-Center for Molecular Medicine, D-13125 Berlin,
Germany
Alzheimer’s disease (AD) is the most prevalent form of dementia, resulting in progressive neuronal death and debilitating damage to
brain loci that mediate memory and higher cognitive function.While pathogenic genetic mutations have been implicated in2% of AD
cases, the proximal events that underlie the common, sporadic form of the disease are incompletely understood. Converging lines of
evidence fromhumanneuropathology, basic biology, andgenetics have implicated loss of themultifunctional receptor LR11 (also known
as SORLA and SORL1) in AD pathogenesis. Cell-based studies suggest that LR11 reduces the formation of-amyloid (A), themolecule
believed to be a primary toxic species in AD. Recently, mutant mice deficient in LR11 were shown to upregulate murine A in mouse
brain. In the current study, LR11-deficient mice were crossed with transgenic mice expressing autosomal-dominant human AD genes,
presenilin-1 (PS1E9) and amyloid precursor protein (APPswe). Here, we show that LR11 deficiency in this AD mouse model signifi-
cantly increases A levels and exacerbates early amyloid pathology in brain, causing a forward shift in disease onset that is LR11 gene
dose-dependent. Loss of LR11 increases the processing of the APP holo-molecule into -, -, and -secretase derived metabolites. We
propose that LR11 regulates APP processing and A accumulation in vivo and is of proximal importance to the cascade of pathological
amyloidosis. The results of the current study support the hypothesis that control of LR11 expression may exert critical effects on
Alzheimer’s disease susceptibility in humans.
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Introduction
Alzheimer’s disease (AD) is the most prevalent form of dementia,
affecting nearly half of elderly persons over the age of 85, and over
5 million individuals in the United States alone. Understanding
of the molecular underpinnings of the disease process has greatly
advanced in the last 20 –30 years; however, the exact molecular
events that trigger the disease cascade remain elusive. Recently,
converging lines of evidence from human neuropathology, basic
biology, and genetics have implicated LR11 (also known as
SORLA and SORL1) in AD pathogenesis. LR11 is a type-1 trans-
membrane protein belonging to both the APOE-binding low-
density lipoprotein receptor family and the vacuolar protein sort-
ing 10 protein (VPS10p) family of intracellular sorting receptors
(Yamazaki et al., 1997; Jacobsen et al., 2001; Herz and Bock,
2002). We first established the connection between AD and LR11
with the observation that LR11 protein is consistently reduced in
vulnerable neurons in AD brain (Scherzer et al., 2004). Recently,
variants of the LR11 gene (SORL1) were shown to correlate with
risk of sporadic AD in several populations, providing direct ge-
netic evidence for a proximal role of LR11 in AD (Lee et al.,
2007b; Meng et al., 2007; Rogaeva et al., 2007; Tan et al., 2007).
-amyloid (A) peptide is the major component of the hall-
mark senile plaques found in AD (Glenner and Wong, 1984). A
is toxic to neurons, and the aggregation of A is believed to
culminate in neurodegeneration and clinical disease. Over the
past two decades, the molecules that control the processing of the
amyloid precursor protein (APP) into A have been intensely
investigated (Weidemann et al., 1989; Gandy and Petanceska,
2000; Ehehalt et al., 2003; Ling et al., 2003; Gralle and Ferreira,
2007). Recent studies have established that LR11 physically inter-
acts with APP and the-site APP cleaving enzyme (BACE-1) and
that overexpression of LR11 reduces A production in cultured
cells (Andersen et al., 2005, 2006; Offe et al., 2006; Spoelgen et al.,
2006). Moreover, mice deficient for LR11 exhibit increased levels
of murine A (Andersen et al., 2005).
In the current study, we explore whether LR11 is capable of
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influencing Alzheimer’s disease-related pathology in vivo. Mice
carrying mutant PSEN1 with Exon 9 deletion (PS1E9) and the
K595M/N596L human “Swedish” mutant APP (APPswe) were
crossed with mice expressing reduced levels of LR11 (Lr11Ex4).
LR11 deficiency results in early increases in both A40 and A42
along with accelerated amyloid deposition in brain. The magni-
tude of these changes correlates directly with LR11 levels. In cor-
tical tissue and primary neuronal cultures, LR11-deficiency pro-
duces significant changes in levels of the secreted metabolites of
APP (APPs) and APP C-terminal fragments (CTFs), suggesting
that loss of LR11 drives increased processing of the APP holo-
protein and increased generation of the A peptide. Recent work
suggests that LR11 expression may play a protective role against
AD, and our current study provides compelling evidence that
LR11 loss directly contributes to early pathogenic events in vivo
through the regulation of cellular APP processing events.
Materials andMethods
Mouse background and breeding. LR11 deficient mice were engineered by
targeted gene deletion of the 5 region of Sorl1 Exon 4 in 129 SvJ/Bl6 mice
(Andersen et al., 2005). In the course of the present study, these LR11
deficient mice were shown to make an unexpected splice variant of LR11
that is expressed at very low levels in brain. We now designate these mice
as Lr11 exon 4 deletion mutants (Lr11Ex4), but given their very low
expression levels and lack of wild-type LR11, we will continue to refer to
these mice as Lr11/. Homozygous Lr11Ex4 (Lr11/) mice were
crossed with heterozygous double transgenic mice carrying the human
PS1 with exon 9 deletion (PS1E9) mutation and the K595M/N596L
“Swedish” APP (APPSwe) mutation, which originally integrated at the
same locus on Bl6/C3 mouse background (Jackson Laboratories)
(Borchelt et al., 1996, 1997; Jankowsky et al., 2004). PS1/APP transgenic
F1 progeny from the first cross were bred to wild-type LR11 hemizygous
mice, and Lr11/, Lr11/, and Lr11/ littermates carrying PS1E9/
APPSwe were used for analysis. In total, 48 mice were analyzed in this
study across 4 different age groups: 3 months (Lr11/ n 6; Lr11/
n 4), 4.5 months (Lr11/ n 5; Lr11/ n 4; Lr11/ n 5), 6
months (Lr11/ n 9; Lr11/ n 5), and 12 months (Lr11/ n
6; Lr11/ n  4). Refer to supplemental Table 1, available at www.
jneurosci.org as supplemental material, for the gender of animals in each
experimental group.
Characterization of LR11 message expression. Total RNA was isolated
from Lr11/, Lr11/, and Lr11/ tissues using the TRIzol reagent
(Sigma) according to the manufacturer’s recommended protocol. Iso-
lated RNA was treated with Turbo DNase Free (Ambion) to remove
contaminating genomic DNA. Two-step reverse transcription-PCR (RT-
PCR) was performed from 1 g DNase-free total RNA using the Super-
Script First-Strand Synthesis System (Invitrogen) with an oligo(dT)
primer, followed by PCR using hi-fidelity AccuPrime Pfx DNA Polymer-
ase (Invitrogen) with Lr11 exon-specific primer sets, each designed to
amplify 1kb regions from the full-length Lr11 transcript (GenBank
Accession# NM_011436). Sequences for the PCR primers used were:
exon 1 sense (5-ATG GCG ACA CGG AGC AGC AGG-3), exon 3 sense
(5-CTT TGG CGT GGG CAA CAA CAG CG-3), exon 4 sense (5-TAC
ATC TTT GTG GAT GCT TAC GCC CAA TAC C-3), exon 4 antisense
(5-CCT GTC AAA GCC CAA GAG GAG GTT GGA GG-3), exon 5
antisense (5-CGT GTT CCT GAA TCA TGA TCC AGG TCT GGC
C-3), exon 7 antisense (5-GGA TGC TTT GTG ACA AAC TGG GCT
GC-3), exon 8 sense (5-CTG ATG CCG AGG ACC AGG-3), exon 15
antisense (5-CAC AGG ACA AGG CAC AGG AGG GC-3), exon 16
sense (5-CTA TCG GAA GAT TTC TGG GGA TAC GTG C-3), exon 22
antisense (5-CCA GAG GGG AGG ACA CTG CTG G-3), exon 23 sense
(5-GCA ACC AGT ACC GCT GCA GCA ACG-3), exon 31 antisense
(5-GGG CAG GCC TCC TCA TCA GAG C-3), exon 32 sense (5-CAA
ACT CCA CTG CCG CCT CCA C-3), exon 40 antisense (5-CCC TCC
GCG GAA GCT CAG G-3), exon 41 sense (5-GCC TGG GCC AAG
ACA GAC TTG GG-3), exon 48 antisense (5-CAT CGT CCT CTC CTA
GGT CAT CCC CTG AGG-3). For each primer set, thermocycling was
performed using the following protocol: (1) 94°C for 2 min; (2) 35 cycles
of 94°C for 30 s, 57.5°C for 30 s, and 68°C for 2 1⁄2 min; and (3) 68°C for
10 min. The amplified RT-PCR products were separated by electro-
phoresis on 1% agarose gels, stained with ethidium bromide, and visual-
ized using the Flurochem 8800 gel documentation system (Alpha Inno-
tech Corporation). Following agarose gel electrophoresis, RT-PCR
products were excised and the DNA recovered using the Qiaquick Gel
Extraction Kit (Qiagen). Purified RT-PCR products were then sequenced
at Lark Technologies using both the sense and antisense PCR primers.
DNA sequencing results were aligned with the wild-type mouse Lr11
mRNA sequence (NM_011436) and analyzed using the AlignX function
of the Vector NTI software suite (Invitrogen).
Identification of LR11 protein by mass spectrometry. LR11 from mouse
brain was enriched by immunoprecipitation, separated by SDS PAGE
and stained with Coomassie Blue G-250. The LR11-containing band was
excised from the gel and digested by trypsin. The digested peptides were
extracted from the gel piece and analyzed by liquid chromatography
coupled with tandem mass spectrometry using an LTQ-Orbitrap hybrid
mass spectrometer (Thermo Finnigan) (Peng and Gygi, 2001). The col-
lected MS/MS spectra were searched against mouse database, and filtered
by matching scores and mass accuracy (15 ppm) to reduce the false
discovery rate to near zero using the target-decoy strategy (Peng et al.,
2003). Namely, the filtering cutoffs were adjusted until all peptide
matches from the decoy database were removed. Finally, the peptide
matches of LR11 were manually verified with assigned product ions.
Tissue collection. Animals were killed and brains hemisected. One
hemisphere was dissected and snap frozen on liquid nitrogen for use in
biochemical measures. The other hemisphere was immersion fixed in 4%
paraformaldehyde for 2 h at 4°C then transferred to 30% sucrose over-
night for preparation for immunohistochemistry.
Tissue preparation for biochemical analysis. Cortical tissue from one
hemibrain of each mouse was lysed in a Konte’s tissue douncer (Pierce)
in PBS with protease inhibitor mixture at 10% weight by volume (100
mg/ml) and further prepared for either ELISA analysis (see below) or
Western blotting. For Western blot analysis of APP metabolites, mem-
brane and soluble fractions were isolated by differential centrifugation at
4°C. Briefly, cortical homogenates were first subjected to a 1000 g spin
to remove nuclei and debris (P1). The supernatant (S1) was spun at
10,000 g for 20 min to pellet larger organelles and membrane proteins
(P2), and the resulting supernatant (S2) was further spun at 100,000 g
to enrich for soluble proteins (S3). The P2 fraction was rinsed with a
high-salt solution (500 mM NaCl) to remove membrane-associated pro-
teins, and further spun at 10,000  g for 20 min to pellet membrane
proteins (P2). Finally, the washed membrane fractions were lysed in
detergent buffer (50 mM Tris base, 150 mM NaCl, 0.5% NP-40, 0.5%
deoxycholate) and released into the supernatant following a 15,000 g
spin for 5 min. The soluble and membrane fractions were further pre-
pared for Western blot analysis described below.
Immunoblotting. Immunoblotting was performed according to stan-
dard procedures. Briefly, cortical tissue fractions were solubilized in Lae-
mmli sample buffer, separated on SDS-polyacrylamide gels and trans-
ferred electrophoretically to PVDF membranes (Immobilon-P;
Millipore). Blots were blocked for 1 h at room temperature using 1
Blocking Buffer (USB Corporation), probed with primary antibodies in
TBS with 0.1% Tween 20 overnight at 4°C and with fluorophore-
conjugated donkey anti-rabbit (Rockland) and donkey anti-mouse (In-
vitrogen) secondary antibodies at room temperature for 1 h. Images were
captured and band intensities quantified using an Odyssey Image Station
(LiCor Biosciences).
Primary antibodies. LR11 antibodies used in this study include: mouse
anti-LR11 at 1:200 [VPS10p domain epitope; used for immunoblotting,
kindly provided by Dr. H. Bujo (Graduate School of Medicine, Chiba
University, Chiba, Japan) (Hirayama et al., 2000)], rabbit anti-LR11
C-terminal domain at 1:2000 [3850.6; used for immunoblotting and
immunohistochemistry, kindly provided by Dr. C. Schaller (Zentrum
fuer Molekulare Neurobiologie, Universitaet Hamburg, Hamburg, Ger-
many) (Hampe et al., 2000)]. Antibody preadsorption to compete out
specific LR11 primary antibody binding for both immunoblotting and
immunohistochemistry was performed using rabbit anti-LR11 CT
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(3850.6) at 1:2000 with 1g/ml free LR11 C-terminal peptide for 30 min
at RT. Antibodies used in Western blot analysis of APP metabolites in-
clude: 6E10 at 1:1000 [mouse monoclonal to human APP sequence
within the A domain between amino acids 1–16 (Invitrogen)], C8 at
1:5000 [rabbit polyclonal to C-terminal domain of APP, kindly provided
by Dr. Dennis Selko (Harvard Medical School, Boston, MA), and 192wt
and 192swe at 1:2000 [rabbit polyclonals to-secretase cleaved fragment
of wild-type (wt) or swedish (swe) mutant APPs, kindly provided by Dr.
Peter Seubert at Elan Pharmaceuticals, Dublin, Ireland]. Amyloid
plaques were immunostained using rabbit anti-A42
(Biosource-Invitrogen).
Histochemical plaque evaluation. Sagittal sections (50 m) were cut
from immersion fixed hemispheres using a freezing microtome and col-
lected into 0.1 M phosphate buffer. Sections were either immunostained
using an A42 specific antibody (Biosource) or stained with 1%
thioflavine-S solution to visualize cored amyloid plaques. For A42 im-
munohistochemistry, immunoperoxidase staining methods on free
floating sections were performed as previously described (Dodson et al.,
2006). Briefly, samples were incubated in affinity-purified rabbit poly-
clonal antibody against A42 overnight at 4°C, followed by a biotinylated
goat anti-rabbit secondary antibody (Vector Laboratories) for 1 h at RT.
Sections were then incubated in avidin-biotinylated horseradish peroxi-
dase complex (Vector Laboratories) and immunoreactivity was visual-
ized with 3,3-diaminobenzidine tetrahydrochloride. For visualization of
cored plaques, separate sections were mounted and dried onto superfrost
slides. Slides were rehydrated for 1 min in dH20 and incubated in 1%
thioflavine-S solution for 10 min at RT, then rinsed in 2 changes of 80%
ethanol and additionally rinsed two times in dH20.
Plaque quantitation. Images of sagittal brain sections were captured
using an Olympus BX51 microscope and Olympus software. Plaque den-
sities were determined in blinded manner by manual plaque count of
thioflavine-S staining or surface area of A42 immunostaining using
MetaMorph Imaging software (Molecular Devices). Plaque quantitation
is represented as an average surface area or mean number of plaques per
tissue section as determined from 4 tissue sections evenly distributed
across 1 mm tissue thickness, medial to lateral (approximately
L2.0 –L3.0).
Sequential amyloid extraction and sandwich ELISA. SDS was added to
total cortical homogenates (100 mg wet weight/ml) at 2% final concen-
tration and tissue samples were sonicated (30 s at level 7; Branson Soni-
fier 250, Krackeler Scientific) and centrifuged at 4°C for 1 h at 100,000
g (Optima TLX Ultracentrifuge; Beckman Coulter). Supernatant was
collected (SDS-soluble fraction) and the pellet was resuspended in equal
volume 70% formic acid in water and sonicated again as described above.
Formic acid fractions were neutralized by 1:20 dilution in 1.0 M Tris base,
pH 10.8. SDS fractions were diluted at least 1:40 and neutralized formic
acid fractions diluted at least 1:50 in ELISA diluent buffer (50 mM Tris
base, 150 mM NaCl, 0.5% NP-40, 0.5% deoxycholate, 0.1 mg/ml phenyl-
methylsulfonyl fluoride, protease inhibitor mixture, pH 7.4). Fractions
were stored at 80°C until ELISA analysis and were not subjected to
more than one freeze-thaw cycle. Sandwich ELISAs specific for full-
length A40 and A42 amyloid species (Genetics Company) were used
to measure A levels according to manufacturer’s instructions. Plates
were read at 450 nm on a Spectra Max Plus plate reader (Molecular
Devices).
Preparation of primary cortical neurons for analysis of APP metabolism.
Primary cultures were prepared from 3 matched sets of Lr11/ and
Lr11/ dams (not crossed to the PS1/APP mice) on embryonic day 18.
Briefly, cortical material was dissected from mouse embryos and
trypsinized. Cell viability was evaluated by trypan blue exclusion. Corti-
cal cells were plated at a density of 80,000 cells/cm 2 in 60 mm tissue-
culture dishes coated with 250 g/ml poly-L-lysine. Cells were main-
tained in neuronal medium (Neurobasal medium (Invitrogen)
containing 5% B-27 supplement, 1% penicillin/streptomycin, 1%
L-glutamine, and 5 M the mitotic inhibitor aramycin-C). On day 3
postplating, cells were infected with wild-type human APP695lentivirus
with a multiplicity of infection1 and allowed to incubate for 72 h. On
day 6 postplating, the viral media was removed and 1.5 ml of fresh neu-
ronal media was added and allowed to condition for 16 h. On day 7,
conditioned media and cells were harvested and prepared for biochem-
ical analysis.
Data analysis and statistics.Given the logarithmic increases in A levels
with advanced age, raw measures were transformed for statistical analysis
and analyzed with nonparametric tests, when possible. To normalize
ELISA measurements of A, data were first transformed by taking the
natural log of raw values, then standardized by calculating the z-score
(individual value  group mean/group SD) within each measure (i.e.,
SDS-soluble fraction of A40, formic acid soluble fraction of A42, etc.).
For combined values (i.e., total soluble A, total A40, etc.), individual
measure z-scores were averaged together. To detect LR11 genotype ef-
fects with age in the PS1/APP mice, a two-way ANOVA was performed
on individual z-scores, followed by pairwise Mann–Whitney nonpara-
metric t tests to compare Ameasures within each age group. For quan-
titative plaque density measurements, raw values were transformed by
taking the natural log and analyzed using a two-way ANOVA, Kruskal–
Wallis one-way ANOVA followed by Dunn’s multiple comparison test,
or Mann–Whitney nonparametric t test. Western blotting analysis of
APP and APP metabolites measured from primary cortical cultures and
tissue preparations were analyzed using Student’s t test. All statistical
comparisons were analyzed using GraphPad Prism (GraphPad
Software).
Results
Lr11/ mice were engineered by homologous recombination
resulting in deletion of the 5 region of Exon 4 within the Lr11
genomic sequence (Andersen et al., 2005). Previously, analysis
using brain membrane preparations indicated absence of the re-
ceptor in mice homozygous for the gene deletion (Andersen et al.,
2005; Ma et al., 2007). However, experimental results in the cur-
rent study using a different set of anti-LR11 antisera suggested
low levels of expression of a truncated receptor from the targeted
gene locus. Therefore, experiments were performed to evaluate
the possible existence of a truncated Lr11 mRNA and LR11 pro-
tein species in brain lysates of LR11 deficient animals.
Lr11 mRNA expression in Lr11/ animals was determined
by RT-PCR. Purified RNA samples from LR11 wild-type (Lr11/
), LR11 deficient (Lr11/), and heterozygous (Lr11/) mice
were subjected to reverse transcription-PCR. Six primer pairs
amplifying 1 kb regions of exons 1–7, 8 –15, 16 –22, 23–31,
32– 40, and 41– 48 were used to examine the integrity of the 6
kb full-length LR11 message. Lr11 RT-PCR products were de-
tected in both Lr11/ and Lr11/ samples using all primer
pairs (data not shown). The size of Lr11 RT-PCR products de-
tected in Lr11/ samples was identical to that of Lr11/ sam-
ples with the exception of the region amplified by primers di-
rected from exon 1 (sense) to exon 7 (antisense). While the RT-
PCR product generated from Lr11/mice migrated on the gel at
the predicted size of 1 kb, the Lr11/ fragment was noticeably
smaller (850 kb) (data not shown). Given that the homologous
recombination strategy used to engineer these mice targeted a
region within exon 4, we hypothesized that the size difference
observed in RT-PCR products generated from the exon 1–7
primer set was due to partial or complete deletion of exon 4.
Amplification of Lr11 cDNA between exons 3 and 5 shows that
Lr11/ mice contain a RT-PCR product 160 base-pairs
smaller than that of wild-type (Fig. 1A). As expected, Lr11/
mice make both the longer (300 bp) and shorter (140 bp)
RT-PCR products. Attempts to amplify cDNA using primer se-
quences directed to the 5 and 3 ends of exon 4 failed to yield a
detectable RT-PCR product from Lr11/ samples, while this
band was observed at the predicted size (160 bp) in Lr11/
and Lr11/ samples (Fig. 1A).
To further characterize this smaller Lr11 transcript, RT-PCR
was performed using a primer set to amplify the cDNA region
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from exons 3–7. The upper and lower bands corresponding to the
wild-type and mutant RT-PCR products were separated by aga-
rose electrophoresis, recovered from the gel, and sequenced.
DNA sequencing results confirm that the genomic region corre-
sponding to exon 4 is absent in the product generated from the
mutant Lr11 allele (Fig. 1A). In Lr11Ex4 mutant mice, the 3 end
of exon 3 is spliced directly onto the 5 end of exon 5 through a
transcriptional event that has not been reported in wild-type an-
imals. This unexpected and hitherto unreported splicing event
results in LR11 message that is exactly 162 bp’s smaller and a
protein that lacks 54 residues within the N-terminal region of the
VPS10p domain.
SDS-PAGE/Western blot of total mouse brain lysates con-
firms the presence of low levels of a truncated LR11 variant in
Lr11/ brain lysates probed with an N-terminal domain anti-
body recognizing the VPS10p domain (data not shown) and an
antibody raised to the LR11 C terminus (Fig. 1B). Preadsorption
of rabbit anti-LR11 CT with LR11 CT peptide eliminates the
observed 250 kDa band in Western blotted Lr11/ samples (Fig.
1B). To further characterize the protein recognized by anti-LR11
antisera in/ and/mice, LR11 from cortical homogenates
was purified by immunoprecipitation and analyzed by tandem
mass spectrometry (MS/MS). The LR11-containing SDS gel band
was trypsinized and the digested peptides were fractionated by
capillary reverse phase HPLC. Eluted peptides were ionized and
transferred into an on-line mass spectrometer, where they were
further separated based on mass-to-charge ratio (m/z). The de-
tected peptide ions were then selected sequentially and frag-
mented to generate specific MS/MS spectra containing its se-
quence information. After database search, we identified LR11 as
the major protein in both samples; 14 individual LR11 peptides
were sequenced a total of 15 times (spectral counts) in Lr11/
brain and 3 individual peptides were sequenced a total of 4 times
in Lr11/ brain (Fig. 1C). Three fully tryptic peptides (R.EN-
QEVILEEVR.D; K.ESAPGLIIATGSVGK.N; K.ITTVSLSAP-
DALK.I) from both sample were matched and a representative
spectrum is shown in Figure 1D. Consistent with the deletion of
exon 4 in Lr11 mRNA, we detected one peptide (K. ASNLLLG-
FDR.S) from exon 4 region in the/ sample digested by tryp-
sin, but we did not detect this peptide in the trypsin-digested
LR11/ sample. Identification of distinct LR11 peptides in
Lr11/ brain by mass-spectometry provides definitive evidence
for the residual protein expression of the Lr11Ex4 variant in this
mouse model.
Immunohistochemistry for LR11 in Lr11Ex4 mouse brain
shows that staining intensity is markedly reduced compared with
control brain (Fig. 2A). Preadsorption of anti-LR11 with the
C-terminal peptide immunogen (PA) eliminates staining on
Figure1. Characterization of LR11 exon 4 deletion variant in Lr11/mice.A, Top, Sequencing results of purified RT-PCR products fromLR11wild-type and LR11mutantmicewere aligned and
show a full deletion of exon 4messenger RNA sequence in Lr11/ samples. Bottom, Single stranded cDNA from Lr11/, Lr11/, and Lr11/ brain samples was amplified between exon 3
and exon 5 (left) andwithin exon 4 (right) and visualized by standard agarose gel electrophoresis. The expected size of the reaction products was 300 nucleotides and 160 nucleotides, respectively.
In exon 3 to exon 5RT-PCR, the expected 300 bpband is observed in Lr11/ sample an additional smaller band is observed Lr11/ samples and is also evident in Lr11/ samples. A fully intact
exon 4 reaction product is detected in Lr11/ and Lr11/ samples but cannot be detected in Lr11/ samples.B,Western blotting for LR11with a rabbit anti-LR11 C-terminal antibody reveals
LR11 protein expression in LR11wild-type (/) and LR11 deficient (/)mice (arrow; left panel). This proteinmigrates at the samemolecularweight as overexpressed LR11 in HEK cell lysates
(HEK/LR11). The LR11-specific band in these samples can be eliminated by preadsorption of the LR11-CT antibody with free LR11 C-terminal peptide (arrow; right panel). C, Summary of mass
spectrometry results collected from Lr11/ and Lr11/ tissue samples: 14 individual LR11 peptides were identified in/ brain and 3 LR11 peptides were identified in Lr11/ brain.
Sequence information for the 3 peptides identified in Lr11/ brain is provided. D, Representative spectrum of fully tryptic LR11 peptide ESAPGLIIATGSVGK identified in Lr11/ tissue by mass
spectrometry.
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mouse brain sections (Fig. 2A), illustrating that the immunore-
activity observed in LR11Ex4 tissue is not attributable to non-
specific primary or secondary antibody binding to tissue. Quan-
titative Western blotting (Fig. 2B) for LR11 expression in
Lr11/, Lr11/, and Lr11/ animals shows that the Lr11/
mice express the truncated Lr11Ex4 form of LR11 at a level at
least fourfold lower than the level of full-length LR11 of the wild-
type mice ( p  0.05), and heterozygous mice carrying both the
wild-type and mutant Lr11 alleles are intermediate in protein
expression level (Kruskal–Wallis, ANOVA, p 0.0154).
To address the function of the mutant receptor, we cloned
Lr11Ex4 into the pcDNA 3.1 mammalian expression vector and
assessed the effect of Lr11Ex4 on A secretion from HEK cells.
Similar to the wild-type receptor, increasing doses of Lr11Ex4 led
to a dose-dependent decrease in secreted A40 (r2 0.908, p
0.0032) (Fig. 2C). These data suggest that the mutant receptor
retains the ability to regulate A formation. In summary, LR11
mutant mice lack the wild-type receptor but express low levels of
an LR11 species missing part of the VPS10p domain encoded by
Exon 4. While the mutant receptor is poorly expressed, it appears
to retain functional activity with respect to A production. Thus,
we conclude that Lr11Ex4 mutant mice are not LR11 knock-outs
per se, but are an excellent in vivo model of LR11 deficiency.
To determine the in vivo effects of LR11 deficiency on amyloi-
dogenesis, mice heterozygous for the Lr11Ex4 allele (Lr11/)
were crossed with mice carrying mutant PSEN1 with Exon 9 de-
letion (PS1E9) and the K595M/N596L human APPswe. Geno-
types of interest for this study were PS1/APP-positive mice ho-
mozygous for both wild-type Lr11 alleles (Lr11/),
heterozygous for wild-type Lr11 and mutant Lr11Ex4 (Lr11/),
and homozygous Lr11Ex4 mutants (Lr11/). Amyloid mea-
sures were taken from cortex of 3, 4.5, 6,
and 12-month-old PS1/APP/Lr11/ and
PS1/APP/Lr11/ animals. Brain lysates
were subjected to sequential SDS and for-
mic acid extraction, and A40 and A42
levels were determined by sandwich
ELISA. See supplemental Table 1, available
at www.jneurosci.org as supplemental ma-
terial, for summary statistics, including the
gender and number of animals analyzed at
each age and raw values from all fractions
measured. The variance in the PS1/APP
animals is not surprising, given the pub-
lished phenotypic variability of this trans-
genic animal model (Jankowsky et al.,
2001, 2004; van Groen et al., 2006). How-
ever, PS1/APP animals on the LR11-
deficient background often exhibited a
statistically higher variance than the LR11
wild-type animals, possibly indicating in-
dividual differences in compensating for
LR11 deficiency. The majority of animals
used in this study were female (n  34),
but when low numbers precluded statisti-
cal comparisons, some males were added
(n  14) and matched as best as possible
between groups.
LR11-deficiency led to a substantial in-
crease in SDS-soluble and formic-acid sol-
uble A in brain. Figure 3A shows increas-
ing total A levels with age (plotted as the
natural log of raw values) in PS1/APP/
Lr11/ and PS1/APP/Lr11/ animals. Significant differences
in A levels between Lr11/ and Lr11/mice are observed at 3
( p  0.0381), 4.5 ( p  0.0079) and 6 months ( p  0.048),
suggesting that loss of LR11 in PS1/APPmice accelerates the early
accumulation of A (two-way ANOVA genotype effect p 
0.0005) (Fig. 3A; supplemental Table 1, available at www.
jneurosci.org as supplemental material). This effect did not vary
with the species of A measured (A40 vs A42), nor with the
fraction measured (SDS-soluble vs formic acid soluble). Com-
pared with LR11 wild-type mice, LR11 deficiency in PS1/APP
mice increased total A levels by700% at 4.5 months of age and
200% at 6 months of age. At 12 months of age, all measures of
A are similar between Lr11/ and Lr11/ animals (Fig. 3A,
supplemental Table 1, available at www.jneurosci.org as supple-
mental material). At this advanced stage of cortical amyloidosis,
the aggressive nature of the PS1 and APP mutations appears to
overwhelm the effects of LR11 loss.
To examine whether LR11 loss could exacerbate amyloid
plaque pathology, histological evaluation of plaque burden was
performed. Figure 3D illustrates amyloid plaque accumulation in
4.5, 6 and 12 month-old PS1/APPmice with (Lr11/) and with-
out (Lr11/) wild-type LR11 expression. A42-stained surface
area (Fig. 3B) and plaque counts of thioflavine-S-positive amy-
loid deposits (Fig. 3C) on sagittal brain sections were used to
quantify the effect of Lr11 genotype on the development of amy-
loid plaque pathology in PS1/APP mouse brain. Similar to ob-
served differences in A levels, LR11’s influence on plaque dep-
osition is most pronounced at early stages of pathology. Amyloid
deposition, as measured by A42 staining in cortex and hip-
pocampus, increases by two to threefold in LR11-deficient ani-
mals at 4.5 months ( p  0.0286) and 6 months ( p  0.0020)
Figure 2. LR11Ex4 protein expression in brain and effect on A secretion. A, Immunohistochemistry was used to visualize
LR11proteinexpressionpattern in Lr11/ (top left) and Lr11/ (topmiddle) coronal cortical sections. LR11 immunoreactivity
(brown) is observed in both Lr11/ and Lr11/ tissue sections, while intensity of immunoreactivity is markedly reduced in
Lr11/ brain. High magnification (insets) shows punctate somatodendritic LR11 immunoreactivity in both Lr11/ and
Lr11/mice. Antibody specificity is demonstrated by eliminating immunoreactivity with preadsorption (PA; top right) of the
LR11 C terminus (CT) antibody with free CT peptide before incubation with tissue. Scale bar, 100m.B, LR11 protein is detected
by Western blot of 4.5-month-old Lr11/, Lr11/, and Lr11/ cortex. Calnexin is shown to demonstrate equal loading.
Densitometric quantitation of LR11 band intensity reveals significant differences in LR11 protein level across genotypes ( p
0.0154).C, The Lr11Ex4proteinwas cloned into pcDNAand transiently transfected at increasingdoses intoHEK293 cells. Lr11Ex4
overexpression induces a dose-related decrease in A secretion.
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compared with wild-type littermates (Fig.
3B) (two-way ANOVA interaction effect
p  0.0001). Total plaque counts in
Lr11/ mice are significantly elevated at
3 months ( p  0.0379) and 6 months of
age ( p  0.002) (Fig. 3C) (two-way
ANOVA genotype effect p  0.0070). As
observed with ELISA measurements of
A, both A42 immunostaining and
thioflavine-S staining in cortex and hip-
pocampus of PS1/APP/Lr11/ and PS1/
APP/Lr11/ animals are comparable at
12 months of age (Fig. 3B,C), suggesting
that LR11 deficiency accelerates amyloid-
osis but does not increase maximal amy-
loid burden.
Unexpectedly, some of the largest dif-
ferences in amyloid measures between
Lr11/ and Lr11/ animals were found
in cerebellum. Compared with control
mice, increases in A42-stained surface
area are evident in PS1/APP/Lr11/mice
at 6 months ( p 0.0295) and 12 months
of age ( p 0.0357) (cerebellar plaque pa-
thology was not consistently observed at 3
month of age) (Fig. 4A) (two-way
ANOVA genotype effect 0.0001). Even
at 12 months of age, when the impact of
LR11 loss appears to be diminished in cor-
tex and hippocampus, there was a5-fold
increase in cerebellar A42-stained sur-
face area. Moreover, quantitative ELISA
measures of cerebellar extracts at 12
months revealed a threefold increase in
A40 levels in Lr11/ animals compared
with Lr11/ littermates (Fig. 4B) ( p 
0.0381). Amyloid deposition in the cere-
bellum of PS1E9/APPswe mice lags behind
cortex and hippocampus, and loss of LR11
in PS1/APP mutant mice dramatically in-
creases cerebellar amyloid pathology in
12-month-old mice.
To establish whether LR11 can regulate
A accumulation in a dose-dependent
manner, we examined Lr11/, Lr11/
and Lr11/ mice at 4.5 months of age. In
cortex, total A42 levels from the 3 groups
were significantly different (Fig. 5A)
(ANOVA p  0.0490). A42 levels were increased 9-fold in
LR11 deficient homozygotes compared with wild-type (Lr11/
 858.9	 347.1 pg/mg tissue vs Lr11/  94.51	 31.11; p
0.05), while A42 levels in heterozygotes were intermediate
(Lr11/  230.3 	 99.33 pg/mg tissue) and not significantly
different from either Lr11/ or Lr11/ mice. There also ap-
pears to be an LR11 expression level effect on amyloid plaque
accumulation. Significant differences in thioflavine-S plaque
counts were seen across the three genotypes (Fig. 5B) (ANOVA
p  0.0388), again with Lr11/ mice (54.63 	 24.79 plaques)
exhibiting a nonsignificant intermediate phenotype between
Lr11/ (34.15 	 13.89) and Lr11/ mice (76.00 	 12.10)
(Lr11/ vs Lr11/ p 0.05). Across all three genotypes, LR11
protein level, as measured on immunoblots, inversely correlates
with A42 staining in cortex (Fig. 5C) (R2 0.433, p 0.0278).
The strong inverse correlation between LR11 protein levels and
A42 accumulation suggests direct regulation of A production
by LR11.
We hypothesized that the mechanism underlying the en-
hanced amyloid pathology in the Lr11/  PS1/APP mice was
increased amyloidogenic processing of APP. To test this, immu-
noblot analysis of APP metabolites was performed in a subset of
PS1/APP/Lr11/ (n  7) and Lr11/ (n  6) cortical tissue
samples. Full-length APP levels were unchanged (Lr11/ 
100.0% / 15.16 vs Lr11/  124.3% / 22.26; p 
0.3740), but we observed increased accumulation of the soluble
-cleaved secreted APP (APPs) in Lr11/ cortical tissue ( p
0.0161), decreased levels of membrane-associated CTF ( p 
0.0133), and decreased CTF ( p  0.0076) (Fig. 6A). We hy-
pothesize that lower steady-state levels of CTFs reflect increased
Figure 3. -amyloidmeasures in Lr11/ and Lr11/ cortex and hippocampus. A, ELISA-quantification of total A levels
in Lr11/ (white bars) and Lr11/ cortex (black bars) at 3, 4.5, 6, and 12months of age. Data points are plotted as the natural
log raw values (see supplemental Table 1, available at www.jneurosci.org as supplemental material, for raw values). Lr11/
mice exhibit significant increases in total A levels at 3 ( p 0.038), 4.5 ( p 0.0079) and 6 months of age ( p 0.048). B,
Amyloid plaque density [mean surface area (pixels) of A42-positive immunoreactivity per tissue section] is significantly in-
creased in Lr11/mice at 4.5 ( p 0.0286) and 6months of age ( p 0.002). C, Total plaque count is significantly increased
in Lr11/miceat 3 ( p0.0379) and6months ( p0.002).D, Qualitative imagesofA42-stainedamyloiddeposits (brown)
in Lr11/ (left) and Lr11/ (right) cortex and hippocampus at 4.5, 6, and 12months of age. Boxed regions of cortex (a) and
hippocampus (b) are magnified and shown as corresponding insets.
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-secretase processing of the membrane-bound stubs, which
leads to increased generation of the A peptide.
Additionally, we used embryonic cortical cultures prepared
from Lr11/ and Lr11/ mice to assess acute levels of APP
metabolites. Rather than analyze an FAD-linked variant, we
sought to establish whether LR11 loss could influence normal
APP695 processing, a question that is more relevant to sporadic
Alzheimer’s disease. Using lentiviral-mediated gene delivery, hu-
man wild-type APP695 was transduced into primary cortical cul-
tures prepared from Lr11/ and Lr11/ embryos (three exper-
iments were performed in quadruplicate). In these experiments,
total APP expression was only increased by twofold to threefold
over endogenous murine APP (data not shown), reducing the
potential for overexpression artifacts. Analysis of APP metabo-
lites was performed by Western blot from conditioned media and
cell lysates (Fig. 6B). We found no difference in transduction
efficiency or expression of full-length human APP in cortical
cultures (Lr11/  100.0% / 6.02 vs Lr11/  104.2%
/ 4.29, p  0.3856). However, secreted APP, normalized to
cell-associated APP, was increased over twofold in Lr11/ con-
ditioned media samples, including both APPs (increased by
227.5%; p  0.0307) and APPs (increased by 224.8%; p 
0.0094). In contrast to cortical tissue analysis, we did not observe
significant alterations in secreted A (data not shown; p 
0.3155), CTF ( p 0.863) or CTF ( p 0.2840) in these pri-
mary culture experiments (Fig. 6B). It is possible that the infec-
tion protocol and conditioning period was not long enough to
resolve alterations in the -secretase-mediated processing events
that control the metabolism of CTFs and generation of A.
Nonetheless, the robust effects on secretion of APPs and APPs
strongly suggests LR11-deficiency in neurons acutely increases
the overall processing, including the amyloidogenic -secretase-
mediated processing, of wild-type human APP. Combined, the in
vivo and in vitromeasures of APP metabolites from Lr11/mice
strongly implicate LR11 as a regulator of APP processing in
neurons.
Discussion
The Lr11Ex4  PS1E9/APPswe mice represent an animal model
that recapitulates the deficiency of LR11 observed in Alzheimer’s
disease. In cortex and hippocampus, LR11 loss potently acceler-
ates amyloid accumulation at the earliest stages of amyloid dep-
osition. At 4.5 months, PS1/APP transgenic mice homozygous
for Lr11Ex4 have a sevenfold increase in amyloid levels and re-
semble 6 month-old PS1/APP mice expressing wild-type LR11.
The connection between LR11 expression and A deposition is
reinforced by the intermediate phenotype of heterozygous mice
(Lr11/) and the inverse relationship between LR11 protein
level and plaque formation in PS1/APP mouse brain. While we
cannot rule out the possible influence of LR11 in the clearance or
degradation of A, alterations in steady-state and acute measures
of APP metabolites in Lr11/ mice suggests that loss of LR11
increases the rate of processing of the APP holo-protein. In a
complementary study, a modest increase in amyloid deposition
was found in a separate model of human amyloidosis in trans-
genic PDAPP mice (Rohe et al., 2008). The accelerated develop-
ment of neuropathology in LR11 deficient mice provides direct
evidence that LR11 expression is intimately tied to molecular
events underlying amyloid accumulation and deposition in vivo.
In older animals, the influence of LR11 loss in cortex appears
to be overwhelmed by the aggressive PS1 andAPPmutations that
drive amyloidosis, but cerebellar amyloid accumulation contin-
ues to show significant differences in LR11 deficient mice (Fig. 5).
Pathologic amyloid deposition in cerebellum is rarely reported in
human AD or transgenic mouse models, but in a handful of FAD
variants, including the PS1E9 mutation, prominent amyloidosis
and plaque formation have been observed in cerebellum of af-
fected individuals and PS1E9/APPswe mice (Mann et al., 2001;
van Groen et al., 2006). It is generally accepted that the cerebel-
lum is less affected by pathology than other regions in sporadic
AD, but this observation is not well understood. What is different
about cerebellum that seemingly protects this region from AD
pathology? One difference may be related to LR11 expression; we
previously reported that cerebellum is spared of LR11 loss in AD
brain (Offe et al., 2006). Given its intimate relationship with APP
and A, preserved expression of LR11 in human cerebellum may
contribute to this phenomenon.
Previous reports by us and other groups have demonstrated
that LR11 can physically interact with APP and modulate the
Figure4. -amyloidmeasures in Lr11/and Lr11/ cerebellum.A, Qualitative images
of A42-stained sagittal sections of Lr11/ (left) and Lr11/ (right) cerebellum at 4.5, 6,
and 12 months of age. Boxed regions are magnified and shown as corresponding insets. B,
Amyloid plaque density [mean surface area (pixels) of A42-positive immunoreactivity per
tissue section] is significantly increased in Lr11/mice at 6 ( p 0.0286) and 12months of
age ( p 0.0357). C, ELISA-quantification of A40 levels (pg/mg tissue) is significantly ele-
vated in Lr11/ cerebellum (black bars) comparedwith Lr11/ littermates (white bars) at
12 months of age ( p 0.0381).
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processing of exogenously expressed APP.
In addition to its interactions with APP,
LR11 has also been linked to both BACE1
and -secretase, the two enzymes that are
necessary for the cleavage of APP and re-
lease of A (Bo¨hm et al., 2006; Nyborg et
al., 2006; Spoelgen et al., 2006). We and
others have also reported that exogenously
expressed LR11 directs the trafficking of
APP away from amyloidogenic cellular
compartments in vitro (Andersen et al.,
2006; Offe et al., 2006; Spoelgen et al.,
2006; Rogaeva et al., 2007; Schmidt et
al., 2007). This hypothesis is supported by
findings that the cytoplasmic domain of
LR11 interacts with Golgi-localized,
Gamma-ear-containing, Arf-binding
(GGA) adaptors that regulate membrane
traffic between the Golgi and endocytic
compartments (Nielsen et al., 2001; Jacob-
sen et al., 2002) and that disrupting inter-
action of LR11 with GGA1 alters APP pro-
cessing fates (Schmidt et al., 2007). A role
for LR11 in control of APP trafficking and
processing is also supported by our obser-
vation that LR11 overexpression in vitro
increases association of APP with endoso-
mal markers, increases non--secretase-
cleaved APP C-terminal fragments, and
decreases A production (Offe et al.,
2006).
The in vitro evidence discussed above
suggests that LR11 has a primary influence
on APP processing, rather than the clear-
ance or degradation of the A peptide. In
the current study, we provide direct evi-
dence linking reduced LR11 expression to
enhanced amyloidosis and altered APP
processing in intact animals and primary
neurons. Our analyses of APP metabolites
in vivo are consistent with findings in cel-
lular models, which suggest that loss of
LR11 increases secretase processing of
APP. Along with increased A, PS1/APP/
Lr11/ mice exhibited increased APPs
and decreased CTF levels in cortical tissue,
implying either the increased exposure of
APP to secretases and/or increased activity
of the enzymes. While changes in BACE1-
cleaved APPs did not reach significance
in cortex, primary cortical neurons from
Lr11/ and Lr11/ embryos revealed
twofold increases in secretion of both -
and -secretase cleaved APP fragments.
Our findings in the PS1E9/APPswe mice
coincide nicely with those from another
recent study in which we found increased
APPs levels in the Lr11Ex4 mouse crossed
to the PDAPP line (Rohe et al., 2008). Therefore, the exacerbated
A phenotype in the LR11-deficient mice is better explained by
APP processing changes than by an effect on A clearance.
The relevance of LR11 loss in human brain is just beginning to
be established. Although the temporal sequence of disease-
relevant molecular events is difficult to establish from patholog-
ical studies, we previously reported that LR11 expression is unaf-
fected by amyloid accumulation in autosomal-dominant,
familial AD cases (Dodson et al., 2006). This finding argues that
LR11 loss is not simply a downstream consequence of other
Figure 5. LR11 gene-dose effects on pathological amyloid measures in 4.5-month-old mice. A, ELISA-measured A42 levels
are significantly different across Lr11/, Lr11/, and Lr11/ genotypes at 4.5months of age ( p 0.049). Lr11/mice
have significantly higher A42 levels compared with Lr11/ mice ( p 0.05). Lr11/ mice are intermediate and not
significantly different from Lr11/ or Lr11/ littermates. B, Total plaque count is significantly different across Lr11/,
Lr11/, and Lr11/ genotypes ( p 0.0388). Lr11/mice exhibit more thioflavine-S-positive plaques per tissue section
than Lr11/ littermates ( p0.05). Lr11/mice are intermediate andnot significantly different from Lr11/or Lr11/
mice. C, Across all genotypes, amyloid plaque density [mean surface area (pixels) of A42-positive immunoreactivity per tissue
section] inversely correlates with LR11 expression levels measured by Western blot ( p 0.0278).
Figure6. APPmetabolite analysis in cortical tissueandprimary cortical neurons from Lr11/and Lr11/mice.A,Western
blot and densitometric quantitation of steady-state APP and relevant APP metabolites in a subset of Lr11/ (n 7) and
Lr11/ (n 6) cortical tissue samples. Membrane proteins and soluble proteins were fractionated by differential centrifuga-
tion and blotted with a panel of APP antibodies, including C8 to visualize full-length APP and CTFs, 6E10 to visualize APPs and
CTF, and 192swe to specifically detect the Swedish formof APPs. For quantitation, APPs levelswere normalized to levels of the
unrelated soluble protein EF1 and CTF levels were normalized to full-length APP. Lr11/ mice exhibit40% increase in
APPs ( p 0.0161) and50% decrease in both CTF ( p 0.0133) and CTF ( p 0.0076). B, Western blot and densito-
metric quantitation of lentivirally transduced APP and APP metabolites from primary cortical culture lysates and conditioned
media (3 independent experiments performed in quadruplicate). Overexpressed wild-type human APP695 is detected by the
human specific 6E10 antibody and other metabolites were detected by the same panel of antibodies described above (with the
exception of 192wt to visualize wild-type APPs). For quantitation, APPs and CTF levels were normalized to over-expressed APP
in each sample. Lr11/ cortical neurons express equivalent levels of full-length APP695, but secrete2-fold more APPs
( p0.0307) andAPPs ( p0.0094) into themedia. Levels of CTFs are unchanged in Lr11/ cortical lysates. EF1 is shown
to demonstrate loading consistency.
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pathological changes, and led us to hypothesize that LR11 loss
could be a primary and early event in AD pathogenesis. Our
current findings in LR11-deficient mice strongly support this
possibility. In addition, we recently reported results of a postmor-
tem study of LR11 in cases of individuals with mild cognitive
impairment (MCI), a clinical condition which often represents
prodromal AD. A subset of MCI cases had significantly reduced
LR11 expression, suggesting that loss of LR11 occurs before overt
clinical symptoms of AD (Sager et al., 2007). The hypothesis that
LR11 loss represents a primary event in AD pathogenesis has been
bolstered by genetic studies, which identified a number of single
nucleotide polymorphisms in the LR11 gene that were modestly
associated with risk of AD in several ethnic populations (Rogaeva
et al., 2007). Interestingly, the reported risk variants are found in
noncoding regions, potentially representing promoter or other
cis-acting elements that may regulate LR11 expression level. In-
dependent studies have identified genetic association between
LR11 variants and cognitive aging (Seshadri et al., 2007), as well
as risk of developing AD in individuals afflicted with Down syn-
drome, an autosomal-dominant disorder that is marked by du-
plication of the APP gene locus (Lee et al., 2007a). Subsequent
studies using sporadic AD samples have reported both positive
and negative associations of LR11 SNPs with AD (Meng et al.,
2007; Tan et al., 2007; Bettens et al., 2008; Lee et al., 2008; Li et al.,
2008; Webster et al., 2008). Interpretation of these genetic studies
is limited by the lack of consistent association of specific variants
with AD in different populations, and the findings must be con-
firmed by further independent studies. Nevertheless, the strength
of the biological evidence powerfully supports the plausibility of a
genetic association between LR11 and risk of common, late-onset
forms of AD.
Our demonstration that loss of LR11 influences APP process-
ing and exacerbates amyloid pathology in vivo in a dose-
dependent manner suggests a tight coupling between LR11 ex-
pression and toxic amyloid accumulation. This finding anchors
the growing connection between LR11 and causal mechanisms of
AD pathogenesis. Neuropathologically, LR11 loss in late-onset,
sporadic AD has been implicated as an early and common event
in vulnerable neurons of human brain. At the cellular level, LR11
directs the trafficking of APP and inhibits A production. Fur-
ther, genetic association studies point to the possibility that LR11
variants mediate late-onset AD susceptibility. Combined, these
observations strongly suggest that neuronal LR11 expression
plays a protective role against AD, and moreover, that loss of
LR11 in human brain may drive the amyloidogenic disease pro-
cess. Here, we provide compelling in vivo evidence that LR11 loss
is indeed intimately tied to proximal molecular events underlying
Alzheimer’s disease pathogenesis.
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